222 related articles for article (PubMed ID: 34418311)
1. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.
Cowan DA; Moncrieffe DA
Drug Test Anal; 2022 May; 14(5):808-819. PubMed ID: 34418311
[TBL] [Abstract][Full Text] [Related]
2. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
3. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
Equey T; Pastor A; de la Torre Fornell R; Thomas A; Giraud S; Thevis M; Kuuranne T; Baume N; Barroso O; Aikin R
J Clin Endocrinol Metab; 2022 Feb; 107(3):649-659. PubMed ID: 34726230
[TBL] [Abstract][Full Text] [Related]
4. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
5. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
[TBL] [Abstract][Full Text] [Related]
6. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
8. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
[TBL] [Abstract][Full Text] [Related]
9. The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters.
Ericsson M; Bhuiyan H; Yousif B; Lehtihet M; Ekström L
Drug Test Anal; 2020 Nov; 12(11-12):1620-1628. PubMed ID: 33125822
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
[TBL] [Abstract][Full Text] [Related]
11. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport.
Abellan R; Ventura R; Pichini S; Pascual JA; Pacifici R; Di Carlo S; Bacosi A; Segura J; Zuccaro P
Clin Chem Lab Med; 2005; 43(1):75-85. PubMed ID: 15653447
[TBL] [Abstract][Full Text] [Related]
13. Biomarker detection of rhGH doping: an excretion study.
Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
[TBL] [Abstract][Full Text] [Related]
14. A correction to the age-adjustment of the GH-2000 score used in the detection of growth hormone misuse.
Böhning D; Böhning W; Guha N; Cowan DA; Bartlett C; Sönksen PH; Holt RIG
BMC Res Notes; 2018 Sep; 11(1):650. PubMed ID: 30185229
[TBL] [Abstract][Full Text] [Related]
15. A Targeted Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Peptides from the Carboxyl-terminal Region of Type III Procollagen, Biomarkers of Collagen Turnover.
Huynh HH; Forrest K; Becker JO; Emrick MA; Miller GD; Moncrieffe D; Cowan DA; Thomas A; Thevis M; MacCoss MJ; Hoffstrom B; Byers PH; Eichner D; Hoofnagle AN
Clin Chem; 2022 Oct; 68(10):1281-1291. PubMed ID: 35906802
[TBL] [Abstract][Full Text] [Related]
16. Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse.
Böhning D; Böhning W; Guha N; Cowan DA; Sönksen PH; Holt RI
BMC Med Res Methodol; 2016 Oct; 16(1):147. PubMed ID: 27793179
[TBL] [Abstract][Full Text] [Related]
17. Combined statistical decision limits based on two GH-2000 scores for the detection of growth hormone misuse.
Liu W; Bretz F; Böhning D; Holt RIG; Han Y; Böhning W; Guha N; Cowan DA
Stat Methods Med Res; 2022 Aug; 31(8):1439-1448. PubMed ID: 35611962
[TBL] [Abstract][Full Text] [Related]
18. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
19. The effect of a period of intense exercise on the marker approach to detect growth hormone doping in sports.
Voss SC; Robinson N; Alsayrafi M; Bourdon PC; Schumacher YO; Saugy M; Giraud S
Drug Test Anal; 2014 Jun; 6(6):582-6. PubMed ID: 24827554
[TBL] [Abstract][Full Text] [Related]
20. Biological Variation Data in Triathletes for Metabolism and Growth-Related Biomarkers Included in the Athlete Biological Passport.
Moreno-Parro I; Diaz-Garzon J; Aarsand AK; Sandberg S; Aikin R; Equey T; Ríos-Blanco JJ; Buño Soto A; Fernandez-Calle P
Clin Chem; 2024 Jul; 70(7):987-996. PubMed ID: 38781424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
